期刊
CANCERS
卷 10, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/cancers10090326
关键词
elderly; lung adenocarcinoma; multiplex immunohistochemistry; brightfield; immunosenescence
类别
资金
- Canceropole PACA, France
- French Government (Agence Nationale de Recherche, ANR) through the 'Investments for the Future' LABEX SIGNALIFE, France [ANR-11-LABX-0028-01]
- Fondation ARC pour la Recherche sur le Cancer, France [ARC SL220110603478]
- CANC'AIR Genexposomic project, France
- Conseil Departemental des Alpes-Maritimes, France
- Region Provence Alpes-Cote d'Azur, France
With underrepresentation of elderly patients with lung adenocarcinoma (LADC) in anti-PD-1/PD-L1 clinical trials, better understanding of the interplay of PD-L1 and tumor-associated immune cells (TAICs) could assist clinicians in stratifying these patients for immunotherapy. One hundred and one patients with LADCs, stratified by age, were included for analysis of PD-L1 expression and density of TAICs expressing CD4, CD8, and CD33, by using multiplex chromogenic immunohistochemistry (IHC) assays and automated digital quantification. The CD4(+)/CD8(+) ratio was significantly higher in elderly patients. In patients <75 years, the density of CD4(+), CD8(+), and PD-L1 in TAICs showed a positive significant correlation with PD-L1 expression in tumor cells (TCs), while a lower correlation was observed in the elderly population. In the latter, a high CD4(+)/CD8(+) ratio, and combined PD-L1 expression >= 1% TCs with a low CD8(+) density, low CD33(+) density, and a high CD4(+) density correlated to worse overall survival. We identified differences according to age in the CD4(+)/CD8(+) ratio and in correlation between PD-L1 expression and the density of TAICs in LADC patients. Distinct groups of tumor microenvironments had an impact on the OS of elderly patients with LADC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据